Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 281.5% in February

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the recipient of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 72,100 shares, an increase of 281.5% from the January 31st total of 18,900 shares. Based on an average daily trading volume, of 42,900 shares, the days-to-cover ratio is presently 1.7 days. Approximately 2.6% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Kiora Pharmaceuticals in a research note on Tuesday, November 12th.

Kiora Pharmaceuticals Trading Down 3.0 %

Kiora Pharmaceuticals stock traded down $0.10 during trading on Friday, hitting $3.25. 13,781 shares of the company were exchanged, compared to its average volume of 41,802. The business’s 50 day moving average is $3.59 and its 200 day moving average is $3.54. Kiora Pharmaceuticals has a 52 week low of $3.00 and a 52 week high of $6.48.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently raised its position in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC increased its stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 200,221 shares of the company’s stock after acquiring an additional 3,670 shares during the quarter. ADAR1 Capital Management LLC owned approximately 6.67% of Kiora Pharmaceuticals worth $661,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 76.97% of the stock is owned by institutional investors.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.